Fig. 5.

Blood NfL levels (GM and 95% CI, top)∗ and relative change from baseline (% reduction in GM and 95% CI, bottom) during the controlled treatment in OPERA I and II (left) and ORATORIO (right). NfL levels were significantly reduced following ocrelizumab treatment in persons with RMS and persons with PPMS, both vs. comparator treatment and vs. baseline levels. GM = geometric mean; HD = healthy donor; IFN = interferon; NfL = neurofilament light; OCR = ocrelizumab; PBO = placebo; pNfL = plasma neurofilament light; sNfL = serum neurofilament light. ∗NfL levels from the HD cohort were adjusted to median ages in OPERA (38 years) and ORATORIO (47 years) to determine median, 10th percentile, and 90th percentile levels. ^†Significant reduction in NfL following ocrelizumab treatment vs. comparator arms; plots show GMs of NfL and 95% CIs.